Outcomes and Control Rates for I-125 Plaque Brachytherapy for Uveal Melanoma: A Community-Based Institutional Experience

Table 3

Univariate analysis on factors impacting.

	HR	95% C.I.
Age
<60	Referent
≥60	2.56	0.58–11.26
Sex
Male	Referent
Female	2.00	0.44–9.06
COMS classification
Small	0.84	0.11–6.13
Medium/large	Referent
T-stage
1	0.68	0.13–3.69
2	Referent
3	1.11	0.16–7.75
4	2.71	0.16–7.73
Equatorial position
Anterior	1.07	0.21–5.46
Spanning	1.66	0.11–25.64
Posterior	Referent
Ciliary body involvement
Not involved	Referent
Involved	1.89	0.12–28.75
Tumor height
<5 mm	Referent
≥5 mm	1.04	0.23–4.67
Plaque margin
<3.5 mm	2.79	26.08–0.30
≥3.5 mm	Referent
Apex dose
<85 Gy	0.33	0.03–3.32
≥85 Gy	Referent
<90 Gy	Referent
≥90 Gy	2.13	0.46–9.76

FFP: freedom from progression; COMS: collaborative ocular melanoma study.